Contra-indicated in patients with moderate to severe hepatic impairment.
Viekira XR is a combined ombitasvir, paritaprevir, ritonavir and dasabuvir extended release tablet.
In May 2018, the FDA announced the discontinuation of Viekira XR with an estimated product availability through until January 1, 2019.
See also separate entries for Ombitasvir/Paritaprevir/Ritonavir (co-packaged with Dasabuvir as Viekira Pak) and Ribavirin.
- TRADE NAME: Viekira XR (AbbVie)
- INDICATIONS: Genotype 1a chronic hepatitis C virus with or without cirrhosis; genotype 1b chronic hepatitis C virus with or without cirrhosis in combination with ribavirin
- CLASS: CYP3A4 inhibitor (ritonavir), Direct-acting antiviral, Hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor (dasabuvir), Hepatitis C virus NS3/4A protease inhibitor (paritaprevir), Hepatitis C virus NS5A inhibitor (ombitasvir)
- HALF-LIFE: 6 hours (dasabuvir); 21–25 hours (ombitasvir); 6 hours (paritaprevir); 4 hours (ritonavir)
- FDA APPROVAL DATE: 07/22/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfuzosin, Carbamazepine, Cisapride, Copanlisib, Dihydroergotamine, Dronedarone, Efavirenz, Ergotamine, Ethinyl estradiol-containing medications, Gemfibrozil, Lovastatin, Lurasidone, Methylergonovine, Midazolam, Midostaurin, Neratinib, Phenobarbital, Phenytoin, Pimozide, Ranolazine, Rifampin, Sildenafil, Simvastatin, St John's Wort, Triazolam - PREGNANCY: Insufficient evidence to inform drug-associated risk; contra-indicated in pregnancy when given with ribavirin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
